Q-omics provides the consensus-scored TMEM255B profile across patient tissues and cancer cell-line models. TMEM255B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM255B is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TMEM255B RNA expression shows 21,257 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UVM, KIRC, and CCRCC as cancer lineages where TMEM255B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM255B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM255B survival associations across molecular data types. TMEM255B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM255B RNA expression–survival associations across cancer types. High TMEM255B expression shows unfavorable associations in UVM, KIRP, LGG, MESO, STAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM255B RNA expression.
This table summarizes TMEM255B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM255B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM255B shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, COAD, HNSC and STAD. The KIRC box plot shows higher TMEM255B RNA expression in tumor versus normal tissue (log2 FC = +1.358, t-test p < 0.001).
This table shows molecular features associated with TMEM255B in patient tissues and cancer cell lines. In patient samples, TMEM255B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM255B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
